Bexsero — A second serogroup B meningococcal vaccine

Medical Letter on Drugs and Therapeutics

Volumn 57, Issue 1482, 2015, Pages 157-159

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BACTERIAL ANTIGEN; FHBP PROTEIN; MENINGOCOCCUS VACCINE; NADA PROTEIN; NHBA PROTEIN; PORIN A; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; 4CMENB VACCINE;

ARTHRALGIA; ASPLENIA; COST; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; MENINGOCOCCOSIS; MYALGIA; NAUSEA; NEISSERIA MENINGITIDIS; NOTE; SERUM BACTERICIDAL ANTIBODY ASSAY; ANIMAL; BLOOD; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; MENINGOCOCCAL INFECTIONS; METABOLISM; PROCEDURES;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B;

EID: 84947775242     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (9)

1. Trumenba: a serogroup B meningococcal vaccine. Med Lett Drugs Ther 2015; 57:5.
2. HM Soeters et al. Serogroup B meningococcal disease outbreak and carriage evaluation at a college — Rhode Island, 2015. MMWR Morb Mortal Wkly Rep 2015; 64:606.
3. LA McNamara et al. First use of a serogroup B meningococcal vaccine in the US in response to a university outbreak. Pediatrics 2015; 135:798.
4. In brief: prevention of meningococcal B disease. Med Lett Drugs Ther 2013; 55:97.
5. T Nolan et al. Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults. Vaccine 2015; 33:4437.
6. KP Perrett et al. Immune responses to a recombinant, fourcomponent, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study. Vaccine 2015; 33:5217.
7. RC Read et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet 2014; 384: 2123.
8. T Folaranmi et al. Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep 2015; 64:608.
9. JR MacNeil et al. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep 2015; 64:1171.